Replies to post #116594 on Triple 000 and Sub-penny Chart Plays

[trader53]

RDAR - Eliminates Debt with 3(a)(10) Transaction

Friday - May 12, 2017
RDAR - RAADR Inc. Completes 3(a)(10)Transaction
and Moves Closer to Being Current on OTC
https://www.accesswire.com/462895/RAADR-Inc-Completes-3a10Transaction-and-Moves-Closer-to-Being-Current-on-OTC


Through the execution
of the 3(a)(10) transaction,
the company will be able to eliminate
debt off of its balance sheet in the coming year.

This transaction will allow the company
to settle with creditors and note holders
and will significantly
improve it's cash flow.

The success of the 3(a)(10)
is greatly dependent on the ability
to prepare and report the financial condition
in an accurate and timely manner.


_______________________________________________________________

Targets 0.0012 / 0.0013 / 0.0014 / 0.0015 / 0.005 / 0.006

RDAR - Targets for Current Status Bounce
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131473891

RDAR - Gap at 0.0010 and 0.0012

* Gaps get Filled !
______________________________________________________________


Embedded and Live! Charts











Embedded Charts

[trader53]

RXMD Climbs from 0.0016 to $0.08 on 3(a)(10) Transaction

Dec 29, 2014
RXMD - Climbs from 0.0016 to $0.08

Dec 29, 2014
Progressive Care Releases Open Letter to Shareholders
The success of the 3(a)(10) Transaction
http://www.otcmarkets.com/stock/RXMD/news/Progressive-Care-Releases-Open-Letter-to-Shareholders?id=94376&b=y

September 2014
RXMD 3(a)(10) transaction initiated

Dec 29, 2014

In August,
we reached our first major accomplishment of the year.
After months of negotiation and hard work,
the company finalized our debt exchange transaction
with Tarpon Bay Partners, LLC.

Through the execution
of the deal with Tarpon Bay and approval by
the Circuit Court for
the 3(a)(10) transaction
to proceed, the company will be able to eliminate
approximately $1.8 million in debt off of its
balance sheet in the coming year.

This transaction allowed the company
to settle its litigations with creditors
and note holders and has significantly
improved our cash flow.

The success of the 3(a)(10)
is greatly dependent on our ability to prepare and report
on our financial condition in an accurate and timely manner.

In September,
we took a great leap forward in this regard
by filing our unaudited year-end financial
statements for 2012 and 2013 through OTC Markets.

These financial statements
were then quickly followed up by the filing
of our unaudited financial statements
for all three quarters of 2014 on November 22nd.

The filings not only presented the company's
current financial position to the public,
but also presented the great strides
the company has made towards achieving
profitability by reducing operating costs
and liabilities and increasing sales.

Moving forward,
we will pursue new avenues of advancement
of the PharmCo brand through mergers and acquisitions.

We believe that key partnerships
with similarly positioned independent pharmacies
will yield economies of scale and unlock
unrealized growth potential.

We will also continue to seek other options
for raising capital to reduce the dilutive pressure
associated with the 3(a)(10) transaction.

December 10, 2015
Progressive Care Inc. Completes 3(a)(10) Transaction
http://www.marketwired.com/press-release/progressive-care-inc-completes-3a10-transaction-otc-pink-rxmd-2081016.htm

As of today, Tarpon Bay Partners, LLP
has confirmed that the 3(a)(10) transaction initiated in September of 2014 has closed.

In total the company has issued
282,275,000 shares of common stock
to eliminate over $1.9 million in aged debt
off of its balance sheet.

The company estimates that of these shares
approximately 12,000,000 shares
will be returned to treasury.